Idioma:

Botulinum toxin treatment in parkinsonism

Anandan, Charenya ; Jankovic, Joseph

Journal of the neurological sciences, 2024-01, Vol.456, p.122810-122810, Article 122810 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
Botulinum toxin treatment in parkinsonism
Autor: Anandan, Charenya ; Jankovic, Joseph
Assuntos: Botulinum Toxins - therapeutic use ; Botulinum Toxins, Type A - therapeutic use ; Dystonic Disorders - drug therapy ; Humans ; Parkinson Disease - drug therapy ; Parkinsonian Disorders - drug therapy ; Tremor - drug therapy ; United States
É parte de: Journal of the neurological sciences, 2024-01, Vol.456, p.122810-122810, Article 122810
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
ObjectType-Review-1
Descrição: Botulinum toxin (BoNT) was approved by the United States Food and Drug Administration (FDA) in 1989 for facial movement disorders and strabismus, but since that time its indications have been expanding beyond neurologic and ophthalmologic disorders. This article is a narrative review of the therapeutic use of BoNT in tremors, dystonia, sialorrhea, bladder and other autonomic symptoms, levodopa-induced dyskinesia and other problems occuring in the setting of parkinsonism. Though FDA approval is lacking for some of these indications, expert experiences have shown that BoNT is often beneficial in this group of patients.
Editor: Netherlands
Idioma: Inglês

Links

Voltar para lista de resultados